You are here: Industry Insights > Janssen

News List

Pharma lacks engagement with mental health groups: report pharmatimes
August 13, 2018
Janssen has come first in a new ranking of pharma companies’ reputation among mental health patient groups - but the report notes that engagement between these groups and companies is mostly quite limited.
EMA issues positive opinion to Janssen’s INVOKANA and VOKANAMET biospectrumasia
August 07, 2018
The positive opinion will now be reviewed by the European Commission, which has the authority to grant approval of the updated label.
Janssen, Bayer to close South Korean plants due to limited demand fiercepharma
August 06, 2018
Another drugmaker will close up manufacturing in South Korea. Janssen Korea will shutter its Hyangnam plant in Hwaseong, South Korea, by 2021, laying off an undetermined number of workers.
Janssen Receives Positive CHMP Opinion to Expand Invokana, Vokanamet americanpharmaceuticalreview
August 03, 2018
Janssen announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA)......
Janssen wins FDA nod for Symtuza but the once-daily HIV drug must now find its place in the market fiercepharma
July 23, 2018
Johnson & Johnson has won FDA approval for a new once-a-day HIV drug, adding to its growing portfolio of treatment options for the condition.
AbbVie and Janssen announce failure of cancer drug Imbruvica in Phase 3 trial pharmafile
July 17, 2018
AbbVie and Janssen have announced that Imbruvica (ibrutinib) failed to achieve the primary endpoint in a late-stage study assessing its use in patients with treatment-naïve diffuse large B-cell lymphoma, an aggressive form of non-Hodgkin lymphoma.
Phase III success for Janssen’s esketamine in treatment-resistant depression pharmatimes
June 21, 2018
Janssen has presented data from pivotal Phase III clinical studies backing use of esketamine spray in treatment-resistant depression.
Janssen debuts promising new cancer data at ASCO pharmafile
June 07, 2018
Janssen took the opportunity at the American Society of Clinical Oncology (ASCO) annual event to present promising new Phase 2 and 3 data on two of its candidates
Janssen terminates Darzalex/Tecentriq combo trial pharmatimes
June 06, 2018
A combination of daratumumab (Janssen’s Darzalex) and atezolizumab (Roche’s Tecentriq) has failed to show any benefit over the latter alone in a mid-stage trial involving patients with pre-treated metastatic non-small cell lung cancer.
Janssen pulls plug on Alzheimer’s candidate pharmatimes
May 24, 2018
The Johnson & Johnson group said liver enzyme elevations had been observed in some study participants who received the drug.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page